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Background: Artemether-lumefantrine (AL) combination therapy is now the most used anti-malarial treatment in
the world. Quality control of AL formulations is still a major challenge in developing countries. Until now, only
liquid chromatographic methods have been reported in the literature for their analysis. Capillary electrophoretic
methods, which present various advantages (low price of capillary, low volumes of electrolyte consumption), may
be an alternative to liquid chromatography methods. In this paper, a reliable method was developed and validated
for the determination of AL in commercial fixed-dose combination tablets commercialized in Côte d’Ivoire.
Methods: Artemether and lumefantrine were determined by microemulsion electrokinetic chromatography using
short-end injection procedure. The two analytes were extracted from tablets by acidified methanol. Pyrimethamine
was used as internal standard. Separation was carried out in an uncoated fused silica capillary, 30 cm long × 50 μm
internal diameter, using an effective length of 10 cm and a microemulsion composed of octane, butanol, sodium
dodecyl sulfate and borate buffer as background electrolyte, a - 500 V.cm-1 electric field and a detection
wavelength of 214 nm.
Results: Artemether, lumefantrine and pyrimethamine were separated in 6 min. The method was reliable with
respect to selectivity towards formulation excipients, linearity of the response function (r2 > 0.998), recovery studies
from synthetic tablets (in the range 99–101%), repeatability (relative standard deviation 1–3%, n = 7 analytical
procedures). Application to four commercial formulations containing 20/120 mg of AL per tablet gave a content in
good agreement with the declared content. However, the electropherogram of one tablet formulation showed the
presence of an ingredient which was not declared.
Conclusion: The developed MEEKC method can be proposed as an alternative method to liquid chromatography
for the determination of artemether and lumefantrine in fixed-dose combination tablet formulations.
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Malaria is the most important infectious disease in the
world, with an estimated 274 million more cases and 1.1
million more deaths between 2001 and 2010 [1]. To im-
prove therapeutic efficacy and delay the development of
resistance, the World Health Organization has since
2001 recommended for antimalarial treatment, the use
of combination therapy based on the synergistic or addi-
tive potential of two or more drugs. Artemisinin-based
combination therapy, using artemether-lumefantrine
(AL) (Figure 1, [2,3]) and artesunate-amodiaquine (AS-
AQ), is currently considered as the first choice treatment
for Plasmodium falciparum malaria in endemic areas.
Tablets and capsules are used in fixed-dose combina-
tions (FDCs) which ensure that the two drugs are taken
together and in correct proportions.
The assay of the active substances in these formula-
tions is difficult due to the polarity difference between
the analytes and the absence of chromophore for artemi-
sinin derivatives (artesunate or artemether) present in
low proportion with respect to the associated anti-
malarial drug (weight ratios of 1/2.7 for AS/AQ and 1/6
for AL). For the assay of AS and AQ in FDCs, high per-
formance liquid chromatography (HPLC) [4-6] and capil-
lary electrophoresis (CE) methods have been proposed [7].
For AL, only HPLC methods [8-12] have been reported.
César et al. [8] were the first authors to propose a HPLC
method allowing a separation of the two analytes (within
5 min.) using a cyano stationary phase, an acetonitrile-
0.05% trifluoroacetic acidin water (60:40, v/v) mobile
phase and a 210 nm detection wavelength. Due to the high
lipophilicity of lumefantrine, a mixture of chloroform and
acetonitrile was used to ensure the complete extraction of
lumefantrine from tablets. Standard addition method was
used for artemether quantitation to compensate its low
absorbance in the extract. Two monographs were pub-
lished in 2009 and 2010 as United States PharmacopoeiaFigure 1 Chemical structure of artemether and lumefantrine with indSALMOUS standard for AL capsules [9] and in the Inter-
national Pharmacopoeia for AL tablets [10]. In both
monographs, an identical gradient ion-pairing method
with detection at two wavelengths (210 nm and 380 nm
for artemether and lumefantrine, respectively) is proposed.
Test solution (0.2 g L-1 for artemether and 1.2 g L-1 for
lumefantrine) is prepared by extracting the active sub-
stances with a complex diluent composed of ion-pair
reagent, water, propanol and acetonitrile. Under the
chromatographic conditions used, artemether and
lumefantrine are eluted at 19 min and 34 min. respectively
and the run time (RT) including the time for column re-
equilibration is about 55 min. In 2011, some authors [11],
stating that no HPLC method had been previously
reported, have developed an isocratic method providing
the separation in 12 min. using an ODS stationary phase,
a mobile phase composed of methanol-trifluoroacetic
acid- triethylamine buffer (80:20, v/v) adjusted to pH 2.8
and a wavelength detection of 210 nm. This paper is quite
confusing concerning the quantitation since a test solution
(0.8 g L-1 for artemether and 4.8 g L-1 in acidified metha-
nol) which is out of the calibration range and has a con-
centration different from the standard solution (0.2 g L-1
artemether and 1 g L-1 lumefantrine) is used. Very recently
Suleman et al. [12] have developed and validated a sta-
bility indicating assay for the simultaneous determin-
ation of AL tablets. After extraction by tetrahydrofuran,
artemether and lumefantrine are separated in isocratic
conditions using a fused-core amide stationary phase
and detection at 210 nm (β- artemether) and 335 nm
(lumefantrine).
A recent exhaustive literature survey on CE methods
applied to anti-malarials [13] has shown that up to date,
there are no CE methods reported for the assay of
artemether and/or lumefantrine as drug substances or in
drug formulations. Since CE presents the distinct ad-
vantage of reduced operating cost and low-cost CEication of pKa and log P values.
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ing countries [14,15] for the quality control of drugs and
detection of counterfeit or substandard formulations, the
possibility of using this technique for the assay of AL in
FDCs formulations is investigated in this paper.
Methods
Chemicals
De-ionized water doubly distilled was used throughout
the study. All chemicals were of analytical grade. Pyri-
methamine used as internal standard (IS), phosphoric
acid, sodium dodecyl sulfate (SDS) and 1-butanol were
purchased from Sigma Aldrich (Saint Quentin Fallavier,
France). Lithium dodecylsulfate (LiDS) was from Fisher
Scientific (New Jersey, United States of America), octane
and di-sodium tetraborate decahydrate from Merck
(Darmstadt, Germany). Artemether and lumefantrine
were obtained from Quimdis (Levallois-Perret, France).
Pharmaceutical formulations, ArtrineW (LIC Pharma,
Abidjan, Côte d’Ivoire), CoartemW (Novartis Pharm, Basel,
Switzerland), CofantrineW (EGR Pharma, Maharashtra,
Inde) and PlasmocidW (Cipharm, Abidjan, Côte d’Ivoire)
were purchased in Côte d’Ivoire. All formulations have a




The microemulsion (ME) was prepared by accurately
weighing 0.81 g octane, 6.61 g 1-butanol, 3.31 g SDS and
89.27 g of 10 mM sodium tetraborate buffer in a 100 mL
flask. The mixture was sonicated for 20 min to form an
optically transparent ME which is stable for at least
three months.
Internal standard solution
The internal standard solution (ISS) was a 200 mg L-1
pyrimethamine solution in methanol – water – phos-
phoric acid (93: 5: 2, v/v/v).
Mixed standard solution of artemether and lumefantrine
Approximately 20 mg lumefantrine and 200 mg artemether
accurately weighed, were transferred into a 20 mL glass
volumetric flask, sonicated and diluted to volume with ISS.
This solution diluted 1/10 (v/v) in the ME was the standard
solution (100 mg L-1 lumefantrine, 1000 mg L-1 artemether,
20 mg L-1 IS).
Lumefantrine test solution
A portion of ten tablets finely powdered, equivalent to
about 10 mg lumefantrine, was transferred into a 10-mL
volumetric flask, sonicated for 20 min. and diluted to
volume with ISS. The supernatant obtained after centri-
fugation (10,000 rpm for 5 min.) and diluted 1/10 (v/v)in the ME was the test solution for lumefantrine (theoret-
ical concentration 100 mg L-1 lumefantrine, 20 mg L-1 IS).
Artemether test solution
A portion of ten tablets finely powdered equivalent to
about 10 mg artemether was transferred into a 10 mL
volumetric flask, sonicated for 20 min. and diluted to
volume with the ISS diluted 1/10 (v/v) in ME. The
supernatant obtained after centrifugation (10,000 rpm
for 5 min.) was the test solution for artemether (theoret-
ical concentration 1000 mg L-1 artemether, 20 mg L-1 IS).
Because of the physical instability of this microemulsion
in the presence of methanol at a concentration higher
than 8% v/v [16], standard and test solutions were
analysed within six hours following their preparation.
Apparatus and operating conditions
All experiments were performed on a Beckman P/ACE
MDQ (Fullerton, CA) CE instrument equipped with a
DAD. All separations were carried out in an uncoated
fused-silica capillary, 30 cm long (10 cm to the detector),
50 μm inner diameter, 375 μm outside diameter
(Beckman), housed in a cartridge with a 200 × 800 μm
detector window. Prior to its first use, the capillary was
washed at 20 psi for 20 min. with a 0.1 M sodium hy-
droxide solution, and then flushed with water for 5 min.
On each working day, starting a sequence, the capillary
was rinsed at 20 psi for 5 min with 0.1 M sodium hy-
droxide, 5 min water and 5 min ME.
The optimal operating conditions were as follows: the
capillary was flushed with the background electrolyte
(BGE) for 2 min. using a rinse vial different from the
two separation vials. Sample introduction (~4 nL) was
performed on the detector side (short-end injection) by
hydrodynamic injection (0.2 psi for 5 s), followed by a
“wait” step in another vial containing the electrolyte to
prevent sample carryover on the outside capillary tip
and contamination of the separation electrolyte. Separ-
ation was carried out at 25°C, applying a - 15 kV voltage
(− 500 V.cm-1) with the UV detector set at 214 nm. Sep-
aration vials were changed after 10 injections to take
into account buffer depletion.
Standard and test solutions were injected in duplicate.
Relative corrected peak areas (RCPA) corresponding to
areas/respective migration times (MTs) of analyte/IS
were used for calculations.
Results and discussion
Method development
The development of a CE method for AL was a rather
difficult task since artemether, which does not have
chromophore, is in low proportion (weight ratio 1/6 with
respect to lumefantrine) in the formulation. Furthermore,
lumefantrine is a highly hydrophobic compound (Figure 1).
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tional long-end injection (effective length, 20 cm) and a
15 kV separation voltage (normal polarity) to keep the
current developed below 100 μA.
Selection of operation mode, electrolyte and separation
conditions
The chemical structure (Figure 1) of artemether and
lumefantrine shows that artemether is a non-ionizable
compound, so that only micellar electrokinetic chroma-
tography (MEKC) and MEEKC can be potential operation
modes for a quantitative analysis of both compounds. In a
previous paper, it was shown [7] that using a SDS-MEKC
method (SDS 30 mM in 25 mM borate buffer pH 9.2,
500 V.cm-1) lumefantrine was not eluted within 60 min.
This was related to its insolubility in the background elec-
trolyte. Addition of an organic modifier (methanol or
acetonitrile) to the BGE at different concentrations up to
30% (v/v) to improve lumefantrine solubility could not
achieve lumefantrine elution. Hence, further investigations
were carried out in MEEKC, since in MEEKC the presence
of a co-solvent (typically 1-butanol or 2-propanol) and an
oil (typically octane or heptane) results in a great solubil-
izing power both for water-insoluble and water-soluble
compounds [17]. MEEKC is particularly well suited for
the analysis of very lipophilic compounds, such as fat-
soluble vitamins or steroids [18,19] and has found a large
use for the lipophilicity determination of chemical sub-
stances [13,20,21].
Several ME systems were investigated (Table 1), which
gave a high resolution (> 5) and an acceptable current
(< 90 μA) within an acceptable elution time. The ME
composed of 0.81% w/w octane– 6.61% w/w 1-butanol–
3.31% w/w SDS– 89.27% w/w 10 mM borate buffer
was selected in the further steps of development, as it
gives the best compromise in terms of baseline, RT and
operating cost by comparison to LiDS. With this ME,
the analytes were eluted within 12 min. with an accept-
able current and a resolution higher than 7, so that
short-end injection technique (sample introduction at
the detector side) could be used to reduce the RT. The ro-
bustness of this injection mode for quantitative analysis inTable 1 Microemulsion systems tested
Composition of the ME
a) 0.81% w/w octane + 6.61% w/w 1-butanol + 3.31% w/w SDS + 89.27% w/w
10 mM borate buffer
b) 0.81% w/w octane + 6.61% w/w 1-butanol + 3.31% w/w SDS + 89.27% w/w
20 mM borate buffer
c) 0.81% w/w octane + 6.61% w/w 1-butanol + 3.31% w/w LiDS + 89.27% w/w
10 mM borate buffer
d) 0.8% w/w octane + 6.6% w/w 1-butanol + 6.0% w/w SDS + 20% w/w isopr
66.6% w/w 25 mM phosphate buffer
Operating conditions: silica capillary, 30 cm (20 cm to the detector); injection 4 nL;capillary zone electrophoresis [22-24], MEKC [25], and
MEEKC [26] has been reported.
Selection of an extraction diluent and injection solvent for
artemether and lumefantrine
The choice of an injection solvent has a significant im-
pact on separation efficiency in MEEKC as in MEKC,
specially for lipophilic compounds [27]. Selection of an ap-
propriate solvent to extract artemether and lumefantrine
from tablets was a difficult challenge since they have very
different polarities. In MEEKC, it is recommended when-
ever possible to dissolve the sample in the MEEKC buffer
[28] to avoid baseline disturbance. However, lumefantrine
is not soluble in the microemulsion but soluble in metha-
nol acidified with phosphoric [11] or formic acid [29]. Be-
cause the use of an organic solvent results in a loss of
efficiency as it disrupts the microemulsion environment
adjacent to the injection zone, the methanolic extract was
diluted (1/10, v/v), in the ME prior injection. In addition,
because there is no stacking effect, low injection volumes
were used to avoid peak broadening. Different injection
volumes (from about 1.6 to 12 nL) were investigated. A
volume of about 4 nL was found to give satisfactory peak
shapes and reasonable signals.
Selection of an internal standard
An IS was needed to take into account possible metha-
nol evaporation during the extraction step, small varia-
tions in the injected volume. In addition, it takes into
account variations due to temperature and electroosmotic
flow (EOF) rate. Benzoic acid, sorbic acid, cinchonine and
pyrimethamine were tested as IS. Pyrimethamine was se-
lected as it gives a resolution > 2 with artemether and do
not increase the analysis time.
Capillary rinse between injections
Different capillary rinse procedures between injections
were investigated. It was found that a short capillary
rinse with the microemulsion was sufficient to obtain ac-
ceptable drift and repeatability of MTs (n = 6; relative
standard deviation (RSD) < 1%). No fouling of the capil-
lary was observed within 50 injections.Current developed, RT and migration order
+ 70 μA; RT around 12 min; MTartemether < MTlumefantrine;
+ 85 μA; RT around 15 min; MTartemether < MTlumefantrine;
+ 60 μA; RT around 10 min; MTartemether < MTlumefantrine;
opanol + +67 μA; RT around 9 min; MTartemether > MTlumefantrine;
baseline disturbance
separation voltage 15 kV (normal polarity); 25°C; λ = 214 nm.
Figure 2 Selectivity towards declared formulation excipients
(A) and electropherograms of artemether (B) and lumefantrine
(C) determinations.
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Due to the lack of chromophore and the need of a sensi-
tive detection for artemether, a 214 nm wavelength was
selected for the determination of both analytes as it gives
the best signal-to-noise ratio for artemether. Specimen
electropherograms of a standard solution and test solu-
tions recorded under the final operating conditions are
given in Figure 2.
Evaluation of method performances
The method was validated according to the international
conference of harmonisation guideline [30].
Selectivity
The non-interference of the ingredients present in the
different commercial tablet formulations analysed (Table 2)
was assessed by injecting placebo solutions of each formu-
lation. No interference was noted at the MTs of the active
substances and internal standard (Figure 2A).
Linearity of the response function
The linearity of the response function (relative corrected
peak area (RCPA) analyte/IS) vs analyte concentration
was assessed by injecting in triplicate mixed standard so-
lutions (in the range 600–1400 mg L-1 for artemether
and 60–140 mg L-1 for lumefantrine) at five concentra-
tion levels corresponding to 60, 80, 100, 120 and 140%
of the target concentration used in the assay. Corre-
sponding regression equations were:
RCPA artemether=ISð Þ ¼ 0:00038 0:00001ð Þ
artemether mg L1
– 0:03 0:03ð Þ; r2 ¼ 0:9998
RCPA lumefantrine=ISð Þ ¼ 0:0346 0:0005ð Þ
lumefantrine mg L1
– 0:002 0:006ð Þ; r2 ¼ 0:9987
with the confidence intervals calculated at α = 0.05.
Analysis of variance showed that the calibration graphs
were linear and intersected the origin, showing that a
single calibration solution may be used for routine
analysis.
Recovery studies
The accuracy of the method was assessed by performing
recovery experiments on laboratory prepared formula-
tions of CoartemW. Three sets of independent determi-
nations were carried out on placebo powder spiked with
known amounts of artemether and lumefantrine corre-
sponding to 80, 100 and 120% of the target concentration.Recoveries of artemether and lumefantrine calculated
against a standard solution at the target concentration
prepared in duplicate are given in Table 3. Mean recover-
ies for artemether and lumefantrine are in the range 100-
101% and 99-100% respectively.
Table 2 Excipients of the commercial formulations
analysed
























Table 3 Recovery data for artemether and lumefantrine from























Amin et al. Malaria Journal 2013, 12:202 Page 6 of 8
http://www.malariajournal.com/content/12/1/202System and procedure precision
System precision was evaluated throughout the study.
Similar MTs, relative MTs and RCPA were obtained in
different circumstances (capillaries from different sup-
pliers, analysis on different days, preparations of differ-
ent microemulsions). In all cases, the RSD of corrected
peak areas was better than 3% (n = 6 injections). These
results confirm the robustness of this microemulsion
previously reported in the literature [16].
The repeatability of the entire analytical procedure
was evaluated by performing seven replicate determina-
tions of artemether and lumefrantrine in commercial
CoartemW tablets. The repeatability expressed as the RSD
was 1.8% for artemether and 3% for lumefrantrine.
Limit of detection and quantitation
The limits of detection (signal-to-noise ratio of 3) and
quantification (signal-to-noise ratio of 10) were evaluated
from standard solutions of artemether and lumefantrine.
Limits of detection were about 164 mg L-1 for artemether
and 3 mg L-1 for lumefantrine, which correspond to 4 mg
of artemether and 3.5 mg of lumefantrine per tablet.
Limits of quantitation were 548 mg L-1 for artemether
and 6 mg L-1 for lumefantrine, which correspond to
13.5 mg of artemether and 12 mg of lumefantrine per
tablet.laboratory prepared formulations of CoartemW
Found amount (mg) Recovery (%) Mean recovery ± RSD (%)
7.73 101.7
7.65 97.2 100.8 ± 3.2
8.48 103.3
9.78 98.1
10.75 104.2 100.5 ± 3.3
10.42 99.0
11.91 100.4
12.43 101.5 100.3 ± 1.2
12.59 99.0
7.64 101.2
7.77 100.0 99.8 ± 1.4
7.72 98.3
10.28 101.2
10.01 98.2 99.3 ± 1.7
10.55 98.3
11.48 97.7
11.85 99.3 98.8 ± 0.9
12.30 99.4
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Four commercial tablet formulations were analyzed for
active substance content with the proposed method. Du-
plicate determinations were carried out except for
CoartemW (seven determinations). The respective amounts
of artemether/lumefantrine were 102.1/98.6, 101.4/98.1,
99.2/96.0 and 96.7/101.2 percent of the declared content
for ArtrineW, CoartemW, CofantrineW and PlasmocidW tab-
lets. The formulations comply with the requirements (90–
110% of the label claim) of the International Pharma-
copoeia. The corresponding electropherograms are
presented in Figure 2B and 2C. An unknown peak is
present in the electropherogram of CofantrineW tablets
which does not correspond to a declared excipient. Its
presence was confirmed in another batch of CofantrineW
tablet.
Conclusion
The aim of this study was to test if CE could be used as
an alternative technique to liquid chromatography for
the assay of fixed-dose combination tablets of AL. We
have shown that MEEKC is well suited for this purpose.
Satisfactory results were obtained for method validation
with respect to selectivity, linearity of the response func-
tion, recovery experiments and precision. In comparison
with the HPLC methods reported in the literature, the
disadvantage of MEEKC method developed is that the
quantitation of the active substances requires the prepar-
ation of two test solutions which increases the analysis
time. However, this method presents several advantages.
The total volume of organic solvent used for analyte ex-
traction is dramatically lower (about five times) than that
used in LC. Concerning the separation step, CE present
the distinct advantage of reduced operating cost in terms
of elution solvent (a few milliliters per day) and capillary
cost (about 4 US dollars for a 30 cm silica capillary). In
contrast, HPLC uses large volumes of mobile phase for
column equilibration and elution and expensive chroma-
tographic columns. Hence, in developing countries where
financial resources are very limited, CE could be the tech-
nique of choice.
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